Johnson & Johnson $JNJ Shares Sold by Ninety One North America Inc.

Key Points

• Ninety One North America cut its Johnson & Johnson stake by 5.3% in the third quarter, selling 15,108 shares and retaining 270,748 shares valued at approximately $71.7 million. Institutional investors own 69.55% of J&J.
• Johnson & Johnson exceeded third-quarter expectations with adjusted EPS of $2.59 and revenue of $25.40 billion, while raising its 2026 adjusted EPS guidance to approximately $11.05–$11.15. However, MedTech sales missed forecasts amid China pricing pressure and European budget cuts.
• The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.1% annualized yield. Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $274.35, though several firms recently lowered targets.

Ninety One North America Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 270,748 shares of the company's stock after selling 15,108 shares during the period. Johnson & Johnson makes up 3.6% of Ninety One North America Inc.'s holdings, making the stock its 5th biggest holding. Ninety One North America Inc.'s holdings in Johnson & Johnson were worth $71,678,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson during the second quarter worth about $28,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock valued at $38,000 after buying an additional 54 shares in the last quarter. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $43,000. Hyposwiss Advisors SA bought a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $42,000. Finally, Polaris Financial Partners bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $56,000. Institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock worth $23,064,544 in the last 90 days. 0.16% of the stock is currently owned by company insiders.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share and revenue of $25.40 billion, exceeding consensus estimates. Revenue increased 5.9% year over year, led by 7.9% growth in Innovative Medicine. J&J Q3 2026 Earnings Call Transcript
• Positive Sentiment: Management raised its 2026 sales and earnings outlook, with guidance of approximately $11.05–$11.15 in adjusted EPS. Executives also highlighted pipeline products and MedTech innovation as potential sources of future growth. JNJ Q3 Earnings Call Highlights
• Positive Sentiment: Morgan Stanley maintained an “overweight” rating, while RBC retained an “outperform” rating, indicating that analysts still see potential upside despite trimming their price targets. Technical analysts also identified support near $246. Morgan Stanley JNJ Price Target
• Neutral Sentiment: Johnson & Johnson plans an enterprise review on December 8 and is targeting a potential mid-2027 spinoff of its DePuy Synthes orthopedics business. These initiatives could clarify the company’s growth strategy but may also create execution and earnings-dilution concerns. J&J MedTech Orthopedics Spinoff
• Negative Sentiment: MedTech sales missed Wall Street expectations, with weakness attributed partly to China pricing pressure and European budget cuts. Investors viewed the device business as a key reason the stock fell sharply following earnings. Johnson & Johnson Stock Falls as MedTech Misses
• Negative Sentiment: Analysts lowered several price targets after the results, citing mixed pharmaceutical trends, acquisition costs, talc-related charges and potential 2027 dilution. The concerns are more significant because JNJ trades at a premium earnings multiple versus the broader market. Analysts Cut JNJ Forecasts

Johnson & Johnson Stock Down 0.1%

Shares of NYSE JNJ opened at $253.68 on Friday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market cap of $611.35 billion, a price-to-earnings ratio of 38.44, a PEG ratio of 2.59 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07. The stock has a 50-day moving average price of $265.73 and a two-hundred day moving average price of $249.57.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.54%. The firm had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter in the prior year, the business earned $2.80 earnings per share. The business's revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.10 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. The Goldman Sachs Group reiterated a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Bank of America restated a "neutral" rating and set a $278.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, September 29th. JPMorgan Chase & Co. upped their target price on Johnson & Johnson from $270.00 to $285.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 29th. Royal Bank Of Canada reduced their target price on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a report on Wednesday. Finally, Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $274.35.

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.